There are currently 1887 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)
NCT04859296
Recruiting
This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
08/04/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Pain, Appetite Loss, Abuse, Drug
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California +1 locations
Conditions: Multiple Myeloma
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: 84000329 - Academic Medical Research Institute, Los Angeles, California +2 locations
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
NCT06122077
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Science 37, Los Angeles, California
Conditions: Lung Cancer Diagnosis
Register for Updates
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317
Recruiting
This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Heart Failure
Register for Updates
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810
Recruiting
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/04/2025
Locations: Research Site, Los Angeles, California
Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Register for Updates
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824
Recruiting
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic sett... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Usc Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: PD-L1-positive Metastatic NSCLC
Register for Updates
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: Cedars Sinai, Los Angeles, California
Conditions: REM Behavior Disorder, Parkinson Disease
Register for Updates
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
NCT06594991
Recruiting
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Advanced Melanoma
Register for Updates
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Valkyrie Clinical Trials /ID# 269935, Los Angeles, California
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
Open-Label Extension of EryDex Study IEDAT-04-2022
NCT06664853
Recruiting
This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/04/2025
Locations: University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California
Conditions: Ataxia Telangiectasia
Register for Updates
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
Recruiting
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/04/2025
Locations: Clinical Site, Los Angeles, California
Conditions: Schizophrenia
Register for Updates